Chicago Equity Partners LLC Raises Stake in Amedisys Inc (AMED)

Chicago Equity Partners LLC increased its position in shares of Amedisys Inc (NASDAQ:AMED) by 12.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 38,460 shares of the health services provider’s stock after acquiring an additional 4,160 shares during the quarter. Chicago Equity Partners LLC owned about 0.12% of Amedisys worth $4,504,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. First Quadrant L P CA bought a new stake in Amedisys in the third quarter valued at about $939,000. Advisors Asset Management Inc. increased its holdings in shares of Amedisys by 67.2% in the third quarter. Advisors Asset Management Inc. now owns 28,567 shares of the health services provider’s stock worth $3,570,000 after acquiring an additional 11,486 shares in the last quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp bought a new position in shares of Amedisys during the third quarter worth about $2,174,000. Navellier & Associates Inc grew its holdings in shares of Amedisys by 148.7% during the fourth quarter. Navellier & Associates Inc now owns 17,558 shares of the health services provider’s stock worth $2,056,000 after buying an additional 10,499 shares in the last quarter. Finally, Bessemer Group Inc. bought a new position in shares of Amedisys during the third quarter worth about $1,025,000. 96.45% of the stock is currently owned by institutional investors and hedge funds.

In related news, insider Michael Paul North sold 5,625 shares of the stock in a transaction that occurred on Wednesday, November 14th. The stock was sold at an average price of $117.57, for a total transaction of $661,331.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David B. Pearce sold 410 shares of the stock in a transaction that occurred on Monday, December 24th. The shares were sold at an average price of $106.61, for a total value of $43,710.10. Following the transaction, the insider now directly owns 11,010 shares of the company’s stock, valued at $1,173,776.10. The disclosure for this sale can be found here. Insiders have sold 12,952 shares of company stock valued at $1,587,677 over the last three months. Insiders own 2.60% of the company’s stock.

Shares of NASDAQ AMED opened at $132.06 on Tuesday. Amedisys Inc has a 52 week low of $54.06 and a 52 week high of $140.91. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.12. The company has a market cap of $4.17 billion, a P/E ratio of 59.76, a P/E/G ratio of 1.72 and a beta of 1.43.

A number of research analysts recently issued reports on the company. Craig Hallum downgraded Amedisys from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $116.00 to $104.00 in a report on Friday, October 26th. Zacks Investment Research upgraded Amedisys from a “hold” rating to a “buy” rating and set a $140.00 price objective for the company in a report on Wednesday, January 23rd. Benchmark downgraded Amedisys from a “buy” rating to a “hold” rating and set a $136.64 price objective for the company. in a report on Tuesday, February 5th. BidaskClub upgraded Amedisys from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 8th. Finally, ValuEngine upgraded Amedisys from a “buy” rating to a “strong-buy” rating in a report on Monday, February 4th. Eight equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $114.62.

TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2019/02/12/chicago-equity-partners-llc-raises-stake-in-amedisys-inc-amed.html.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

See Also: Current Ratio

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply